论文部分内容阅读
目的观察吉非替尼(Gefitinib,ZDl839)作为一线化疗方案治疗肺结核合并非小细胞肺癌的治疗效果及毒副作用。方法19例活动性肺结核合并经病理学确诊的非小细胞肺癌患者,抗结核药物同时应用吉非替尼(250mg,1次/d,口服)治疗直至病情进展或出现严重不良反应。结果19例肺结核病灶均吸收好转,菌阳病例转阴。肺癌评效:获得CRl例(5.26%),PR5例(26.32%),有效率(RR)为31.58%;SD6例(31.58%);疾病控制率(DCR)为63.16%;PD7例(36.84%)。与药物相关的不良反应依次为:皮疹9例(47.37%),腹泻6例(31.58%),恶心3例(15.79%),关节痛2例(10.53%),肝功能异常2例(10.53%)。尚无因不良反应需停药者。结论吉非替尼治疗肺结核合并非小细胞肺癌疗效明确,患者耐受性好,吉非替尼并不增加抗结核药物的毒副作用。
Objective To observe the therapeutic effect and side effects of gefitinib (ZDl839) as a first-line chemotherapy regimen in the treatment of pulmonary tuberculosis complicated with non-small cell lung cancer. Methods Nineteen patients with active pulmonary tuberculosis complicated with pathologically diagnosed non-small cell lung cancer were treated with gefitinib (250 mg once daily, orally) until the disease progressed or serious adverse reactions occurred. Results 19 cases of pulmonary tuberculosis were better absorption, positive bacteria positive cases. Lung cancer evaluation: CR1 cases (5.26%), PR5 cases (26.32%), the effective rate (RR) was 31.58%; SD6 cases (31.58%); disease control rate (DCR) was 63.16%; PD7 cases (36.84% ). There were 9 cases of rash (47.37%), 6 cases of diarrhea (31.58%), 3 cases of nausea (15.79%), 2 cases of arthralgia (10.53%) and 2 cases of liver dysfunction ). No need to stop due to adverse reactions. Conclusion Gefitinib treatment of pulmonary tuberculosis with non-small cell lung cancer clear effect, patients with good tolerance, gefitinib does not increase the side effects of anti-TB drugs.